Veriheal

DECEMBER 14, 2021

In accordance with this, a new study found that states with legal cannabis markets have been less likely to experience incidences of EVALI, suggesting that properly regulated vape pens are not the problem. An Analysis of Nationwide EVALI Data. ” The study also discovered impacts from other variances in policies across states.

Data 98

Data Vaping Legalization Consumption 98

The Cannigma

JANUARY 16, 2021

Listen & Subscribe: Finding the right cannabis product can be a daunting task for anyone, let alone a new medical patient without any guidance. “That’s not really available in the cannabis industry,” he explained on the Cannabis Enigma podcast. Produced by Elana Goldberg and Michael Schaeffer Omer-Man.

Data 100

Data Research and Development Patients Strains 100

Veriheal

APRIL 11, 2024

Medical cannabis is more popular than ever before, with 38 states having legalized some form of it for various health conditions. This data aligns with Americans’ rising acceptance of cannabis. The most popular qualifying conditions continue to be chronic pain and PTSD, some of which may be related to the pandemic.

Patients 108

Patients Chronic Pain Marijuana Conditions 108

Cannabis Law Report

AUGUST 23, 2022

A panel of Commonwealth Court judges has ordered the Wolf administration to reveal how many medical marijuana patients have received approval from a doctor to use cannabis for opioid addiction treatment. For more than a year, the Department of Health has fought to keep that information secret.

Data 52

Data Treatment Patients Chronic Pain 52

Veriheal

APRIL 23, 2024

Cannabis use is increasing all around the world. These surveys explore the motivations and methods behind cannabis usage for both medical purposes and recreational enjoyment. In this piece, we aim to delve into the use of cannabis among Generation Z (those born between 1997 and 2012) for purposes of happiness, healing, and relief.

Chronic Pain 109

Chronic Pain Data Edibles Sleep 109

NORML

JUNE 19, 2020

The daily use of cannabis by patients with chronic pain conditions is associated with prolonged improvements in pain management and subjects’ overall quality of life, as well as sustained reductions in the use of opioids, according to longitudinal data published in the journal Pain Medicine. ’

Patients 349

Patients Chronic Pain Treatment Therapy 349

Cannabis Law Report

AUGUST 20, 2022

CHICAGO — Governor JB Pritzker and the Illinois Department of Financial and Professional Regulation (IDFPR) today issued three additional Conditional Adult Use Dispensing Organization Licenses to applicants selected in lotteries held in the summer of 2021. Secretary of the Illinois Department of Financial and Professional Regulation.

Conditions 52

Conditions Dispensary Programs Business 52

SpeedWeed

MARCH 30, 2021

THE UK’s first National Health Service patients registry will start collating data from Thursday this week in a significant move for medical cannabis in the country. The development has been welcomed and comes as the nation’s doctors are said to be shifting their cultural stance from viewing ‘cannabis as a dirty word’.

Data 52

Data Patients Clinical Trials Business 52

NORML

JUNE 18, 2019

The administration of herbal cannabis is safe and effective in patients diagnosed with fibromyalgia, according to clinical data published this month in the Journal of Clinical Medicine. Israeli investigators assessed the use of cannabis over a six-month period in 211 patients with the disease.

Patients 279

Patients Therapy Data Safety 279

Cannabis Law Report

JULY 27, 2021

His first initiative is co-authoring an original study on epilepsy using survey data gathered from RoC’s innovative Observational Research Registry (ORR). The ORR is a web-based research platform open to adults and adult caregivers of dependents who are, or are considering, the use of cannabis or hemp products for therapeutic purposes.

Data 105

Data Epilepsy Research and Development Clinical Trials 105

Medicinal Marijuana Association

FEBRUARY 10, 2024

With over 100 known cannabinoids in cannabis, staying informed about the latest research is crucial for making informed decisions. But where do you begin when it comes to navigating the ever-evolving landscape of cannabis studies? Key Takeaways Stay updated with reliable sources to understand latest cannabis research.

Research and Development 52

Research and Development Data Chronic Pain Conditions 52

SpeedWeed

MARCH 14, 2021

Big data and technology have become critical to a wide variety of industries in recent years, and the cannabis industry is no exception. Today, databases, predictive analytics, artificial intelligence , and machine learning are having widespread effects on cannabis businesses, investors, regulators, and consumers. Reduce costs.

Data 52

Data Research and Development Marijuana Collective 52

NORML

JUNE 10, 2020

The agency’s call for comments, initially posted on April 17 at regulations.gov here , states: “Interested persons or organizations are invited to participate by submitting written views, recommendations, and data related to perspectives on and experiences with pain and pain management. percent in 2016).”

Chronic Pain 242

Chronic Pain Therapy Patients Topical 242

NORML

JANUARY 31, 2019

Seventy-five percent of military veterans say that they would consider using either “cannabis or cannabinoid products as a treatment option,” according to member survey data compiled by the group Iraq and Afghanistan Veterans of America (IAVA). The organization represents over 400,000 veterans nationwide.

Clinical Trials 192

Clinical Trials Chronic Pain Data Treatment 192

Veriheal

FEBRUARY 21, 2023

As medicinal and recreational cannabis legalization continues to sweep across the United States, a recent study paints a concerning portrait of many states denying or restricting medical marijuana (MMJ) access. Why Do MMJ Patients Use Cannabis? Many patients take MMJ for more reasons than one.

Access 98

Access Patients Chronic Pain Conditions 98

Veriheal

NOVEMBER 21, 2023

Veriheal remains dedicated to supporting the next generation of pioneers through its Innovation in Cannabis Scholarship. This year, we are proud to continue our investment in the next generation of cannabis industry leaders. Their one-of-a-kind innovations and solutions are invaluable to the future of cannabis.

Research and Development 106

Research and Development Consumption Education Data 106

NORML

MAY 26, 2020

The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. Additional information regarding cannabinoids and pain appears online h ere.

Clinical Trials 251

Clinical Trials Chronic Pain Cannabinoids Patients 251

Cannabis Law Report

JULY 7, 2021

New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. Data also demonstrated that none of the biological drugs selected for the comparison study proved to be anti-proliferative to any of the primary cell types assessed. For more information, visit www.mymd.com.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

NORML

NOVEMBER 25, 2019

Patients suffering from persistent pain conditions who frequently use cannabis are far less likely to use non-prescription opioids, according to longitudinal data published in the journal PLOS One. Authors reported “an independent negative association between frequent cannabis use and frequent illicit opioid use.”

Chronic Pain 280

Chronic Pain Patients Therapy Data 280

Cannabis Law Report

AUGUST 23, 2021

The TGA recently released a new medical cannabis dashboard detailing a variety of information on both SAS-A and SAS-B approvals. Since launching the SAS-B approval pathway, the TGA has processed more than 148,000 applications to access one of the many medical cannabis products available. Pondering Pot has the story.

Chronic Pain 105

Chronic Pain Concentrates Conditions Data 105

NORML

FEBRUARY 25, 2020

Trauma patients administered oral THC consume fewer opioids than do similarly matched controls, according to clinical trial data published in the journal Trauma Surgery & Acute Care. These opioid-sparing effects were most pronounced among participants who had prior experience with cannabis.

Clinical Trials 232

Clinical Trials THC Consumption Therapy 232

Veriheal

DECEMBER 14, 2023

There is a persistent and common belief throughout society that using cannabis over an extended period of time (or, in some cases, even once) can lead to a decline in mental abilities and function. The results were pleasing – researchers found no significant difference in cognitive ability before and after participants consumed cannabis.

Chronic Pain 120

Chronic Pain Consumption Cannabis Marijuana 120

Cannabis Law Report

NOVEMBER 14, 2019

Survey of more than 10,000 people by the Centre for Medicinal Cannabis shows might higher incidence than previously thought reports inews UK. million adults are now using “street cannabis ” to treat the symptoms of chronic conditions , according to the largest poll of its kind. They write. New guidelines.

Conditions 45

Conditions Data Medicine Collective 45

Cannabis Law Report

AUGUST 14, 2019

Let’s take a closer look at five key ways big data and technology are directly impacting the industry. Big Data Streamlines the Marijuana Regulatory Process and Helps Close the Scientific Research Gap. Therefore, the growing marijuana market lacks the clinical data needed to help marijuana businesses create new and better products.

Data 45

Data Research and Development Marijuana Collective 45

Veriheal

JANUARY 26, 2023

Bipolar disorder is a complex condition that impacts millions worldwide, leading to extreme mood swings, intense emotional episodes, and difficulty managing day-to-day life. According to recent research, cannabis could offer unique benefits as part of an approach to managing bipolar disorder.

Treatment 98

Treatment Cannabinoids Conditions Pharmaceutical 98

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients. About RYAH Group, Inc.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Veriheal

AUGUST 17, 2022

Cannabis’ impact on health is a subject area rife with misunderstanding and controversy. Recently, a study found that cannabis users are more likely to end up needing emergency care, claiming that “cannabis use is not as benign and safe as some might think.” Cannabis Consumers at the Hospital .

Research and Development 104

Research and Development Topical Data Cannabis 104

Veriheal

FEBRUARY 9, 2023

The data collected so far by the Turner Institute for Brain and Mental Health at Monash University in Australia suggests that psilocybin not only makes the process more comfortable but, as one participant described, MRIs become “magical.” All imaging and behavioral data will be accessible to the public after the study is complete.

Clinical Trials 98

Clinical Trials Research and Development Data Collective 98

Cannabis Law Report

JUNE 23, 2021

Medicann is a premier cannabis-specialized clinic, providing patients with access to local specialist doctors and pharmacists that have experience prescribing cannabis-based medication. a global leader in the cannabis industry serving both medical and consumer markets and dedicated to helping people improve their lives.

Programs 100

Programs Data Events Collective 100

MMJ Recs

MAY 3, 2024

The Arkansas medical marijuana program, established through the Arkansas Medical Marijuana Amendment in 2016, has paved the way for patients suffering from a variety of debilitating conditions to find relief and improved quality of life. Typically, medical marijuana cards need to be renewed annually.

Marijuana 52

Marijuana Treatment Compliance Compliance 52

Cannabis Law Report

MAY 10, 2022

Anxiety and sleep disorders were some reasons given for prescriptions despite lack of evidence for cannabis treatment, researchers find. The researchers’ analysis found anxiety was the reason given for 16% of medicinal cannabis prescriptions. of prescriptions were for sleep disorders. of prescriptions were for sleep disorders.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Veriheal

MARCH 29, 2023

Several studies have been investigating the possibility of psychosis resulting from cannabis use. However, a 2023 study debunks many myths about the potential dangers of legalizing cannabis. How Several Sources of Data Were Used in the Research In 2019, an estimated 48.2 Following more than 63 million participants from Jan.

Legalization 57

Legalization Data Policy Cannabis 57

Veriheal

AUGUST 15, 2022

Cannabis, a plant wrongly accused of causing laziness and tiredness in consumers, could actually offer fatigue-fighting benefits. This is according to a group of researchers from the University of New Mexico (UNM) , who recently teamed up with the creators of the Releaf App to investigate the true link between cannabis use and energy levels.

Treatment 96

Treatment Research and Development Sativa Cannabinoids 96

Veriheal

MAY 30, 2023

A new 2023 study published in BMJ Supportive & Palliative Care suggests that cannabis could be the answer millions of cancer patients have been looking for. of the patients reported pain as their primary motivation for obtaining a medicinal cannabis prescription. years between May 2015 and October 2018. Interestingly, 72.5%

Medicine 98

Medicine Treatment Patients Data 98

Canna Law Blog

JANUARY 17, 2023

In November 2022, the OLCC adopted and amended a suite of cannabis rules that became effective January 1, 2023. Now that Oregon’s new cannabis rules are effective, let’s take a look at some of the important changes to the rules governing the Oregon industry. Change in business structure. Our thoughts (good and bad) are here.

Retail 70

Retail Cannabis Conditions Business 70

Cannabis Law Report

DECEMBER 14, 2021

(“IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. Food and Drug Administration (FDA) on December 1, 2021. Claudia Grimaldi. info@igcinc.us

Clinical Trials 52

Clinical Trials Safety Data Patients 52

The Cannigma

MARCH 14, 2023

During the height of cannabis prohibition, admitting consumption was very risky. Not only was the identity of “cannabis consumer” tied to stereotypes such as laziness , lack of success and ambition and “a motivational syndrome”, it could result in incarceration and the strict collateral sanctions associated with a drug charge.

Policy 96

Policy Research and Development Conditions Consumption 96